ProCE Banner Activity

MONALEESA-3/-7 Pooled OS Analysis: Ribociclib Plus ET in Patients With HR+/HER2- Advanced Breast Cancer and Visceral Metastases

Slideset Download
Conference Coverage
Ribociclib plus ET associated with prolonged OS and PFS in patients with HR+/HER2- breast cancer and visceral metastases.

Released: June 03, 2020

Expiration: June 02, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono